Adequate methods to identify which @entity2 @entity1 are most likely to benefit from the targeted drugs against both @entity4179 receptor/ @entity4179 ( @entity470 /EGF) are needed. For this reason, we evaluated both the tissue reactivity of ior egf/r3 monoclonal antibody (Mab) in @entity1 @entity2 and its biological activity in NCI-H125 cells. Additionally, we assessed the tissue expression of EGF using two Mabs, CB-EGF1 and CB-EGF2. The overexpression of @entity470 was detected in 33.33% and 62.71% of @entity151 ( @entity151 ) and @entity1149 ( @entity1149 ), respectively. The ability of ior egf/r3 Mab to bind the extracellular domain of @entity470 inhibiting cell proliferation and inducing apoptosis in NCI-H125 cells was also demonstrated. The EGF expression was observed in about 17% and 70% of @entity151 and @entity1149 , respectively. However, differences in the reactivity of CB-EGF1 and CB-EGF2 were evidenced. A dual expression of @entity470 and EGF was observed in 16.67% and 57.63% of @entity151 and @entity1149 @entity1 , respectively. But, a correlation between them was only obtained in @entity1149 . Our results permit to recommend the development of diagnostic kits using ior egf/r3 and/or CB-EGF1 Mabs in order to achieve a better selection of @entity1 to @entity470 /EGF-targeting treatment.

Immunohistochemical Characterization of Three Monoclonal Antibodies Raised against the @entity4179 and Its Receptor in Non-Small-Cell Lung Cancer: Their Potential Use in the Selection of XXXX for Immunotherapy.

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity470 :: ('1956', 'Gene') :: ['EGFR'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer', 'lung carcinomas'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung carcinoma'] @entity4179 :: ('1950', 'Gene') :: ['epidermal growth factor'] @entity151 :: ('MESH:D055752', 'Disease') :: ['small-cell lung carcinoma', 'SCLC']
@entity1 :: (9606,Species) :: ['Patients']
